Tetanus
📧 Sign up to get email alerts when something new happens for Tetanus.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-17Clinical Trial Update: A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Healthy Japanese Adolescents Aged 11 Years to <13 Years [Phase 3]
Phase 3 trial evaluating immune response and safety of a combined diphtheria-tetanus-acellular pertussis vaccine (dTpa) in healthy Japanese …
-
EMA approval · 2026-08-07EMA Authorised: Hexyon (filamentous haemagglutinin;Haemophilus influenzae type B polysaccharide (polyribosylribitol phosphate);hepatitis B surface antigen;pertussis toxoid;poliovirus (inactivated) type 1 (Mahoney strain) produced on Vero cells;poliovirus (inactivated) type 2 (MEF-1 strain) produced on Vero cells;poliovirus (inactivated) type 3 (Saukett strain) produced on Vero cells;tetanus protein;tetanus toxoid adsorbed on aluminium hydroxide, hydrated;Diphtheria toxoid) — Sanofi Winthrop Industrie
EMA has authorised Hexyon, a combined immunization vaccine covering multiple diseases including hepatitis B, diphtheria, tetanus, pertussis,…
-
EMA approval · 2026-07-10EMA Authorised: Infanrix Hexa (Diphtheria toxoid;tetanus toxoid;Bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin);hepatitis B surface antigen;poliovirus (inactivated) (type-1 (Mahoney strain), type-2 (MEF-1 strain), type-3 (Saukett strain));Haemophilus influenzae type b polysaccharide) — GlaxoSmithKline Biologicals S.A.
EMA has authorised Infanrix Hexa, a hexavalent vaccine by GlaxoSmithKline Biologicals S.A., covering multiple antigens including diphtheria,…
-
CLINICAL_TRIALS trial_result · 2026-07-02Clinical Trial Results: Safety and Immunogenicity Study of Tdap Vaccinations for Plasma Donors [Phase 2]
Phase 2 trial evaluating safety and immunogenicity of Tdap vaccinations in plasma donors; results completed with posted results.
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Tetanus Severity Score for Prediction of Mortality in Manifest Tetanus
A clinical trial from Ain Shams University is evaluating a Tetanus Severity Score to predict mortality in patients with manifest tetanus and…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-03-31EMA Authorised: Vaxelis (Diphtheria toxoid;tetanus toxoid;Bordetella pertussis antigens: pertussis toxoid, filamentous haemagglutinin, pertactin, fimbriae Types 2 and 3;hepatitis B surface antigen produced in yeast cells;poliovirus (inactivated): type 1 (Mahoney), type 2 (MEF-1), type 3 (Saukett) produced in Vero cells/ Haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to meningococcal protein.) — MCM Vaccine B.V.
The EMA has authorised Vaxelis, a combination vaccine containing diphtheria and tetanus toxoids, pertussis antigens, hepatitis B surface ant…
-
CLINICAL_TRIALS research · 2026-03-25Clinical Trial Update: A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents) [Phase 1]
A Phase I clinical trial update for an absorbed acellular pertussis–diphtheria–tetanus vaccine intended for adults and adolescents; the stud…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy [Phase 4]
Phase 4 clinical trial evaluating concurrent versus sequential administration of Tdap and an RSV vaccine in pregnant individuals.
-
CLINICAL_TRIALS safety_alert · 2026-03-03Clinical Trial Update: Safety Monitoring of Boostagen® Vaccine in Thailand
A safety monitoring update for Boostagen Vaccine in Thailand indicates the study safety monitoring has been completed, with the vaccine bein…
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: TETANUS Antibody Detection in Saliva Study [NA]
University of Birmingham is conducting a study to detect tetanus antibodies in saliva; the trial is currently not recruiting.
-
CLINICAL_TRIALS other · 2026-02-18Clinical Trial Update: Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine [Phase 1, Phase 2]
This entry notes a Phase I/II clinical trial evaluating a reduced-dose Diphtheria-Tetanus-Pertussis vaccine; the study is not yet recruiting…
-
EMA approval · 2026-02-12EMA Authorised: Infanrix Hexa (Diphtheria toxoid;tetanus toxoid;Bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin);hepatitis B surface antigen;poliovirus (inactivated) (type-1 (Mahoney strain), type-2 (MEF-1 strain), type-3 (Saukett strain));Haemophilus influenzae type b polysaccharide) — GlaxoSmithKline Biologicals S.A.
The European Medicines Agency authorised Infanrix Hexa, a hexavalent vaccine that combines diphtheria, tetanus, pertussis, hepatitis B, poli…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection [Phase 1]
Phase 1 clinical trial evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of a recombinant human anti-tetanus toxin mon…
-
CLINICAL_TRIALS research · 2026-01-16Clinical Trial Update: A Phase 4 Study to Evaluate the Effectiveness and Safety of Siltartoxatug Injection for Tetanus Prophylaxis Following Injury
Phase 4 clinical trial evaluating the effectiveness and safety of Siltartoxatug Injection for tetanus prophylaxis after injury; study status…
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: A Registry： Siltartoxatug Injection for Tetanus Prophylaxis Following Injury
A registry entry describing a clinical trial evaluating Siltartoxatug Injection for tetanus prophylaxis after injury, which is currently rec…
-
CLINICAL_TRIALS research · 2025-12-31Clinical Trial Update: Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine [Phase 1]
This is a Phase 1 clinical trial evaluating an adsorbed, acellular pertussis vaccine component combined with Hib and ACWY meningococcal comp…
-
CLINICAL_TRIALS trial_result · 2025-12-30Clinical Trial Update: PFAS Exposure and Immune Response to Vaccination in Adults [Phase 4]
Phase 4 clinical trial update assessing whether PFAS exposure alters the immune response to vaccination in adults; results have been posted.
-
EMA approval · 2025-09-29EMA Authorised: Hexyon (filamentous haemagglutinin;Haemophilus influenzae type B polysaccharide (polyribosylribitol phosphate);hepatitis B surface antigen;pertussis toxoid;poliovirus (inactivated) type 1 (Mahoney strain) produced on Vero cells;poliovirus (inactivated) type 2 (MEF-1 strain) produced on Vero cells;poliovirus (inactivated) type 3 (Saukett strain) produced on Vero cells;tetanus protein;tetanus toxoid adsorbed on aluminium hydroxide, hydrated;Diphtheria toxoid) — Sanofi Winthrop Industrie
EMA authorised Hexyon, a hexavalent vaccine combining protection against hepatitis B, diphtheria, tetanus, pertussis, Haemophilus influenzae…
-
EMA approval · 2025-09-29EMA Authorised: Hexacima (hepatitis B surface antigen;Diphtheria toxoid;Bordetella pertussis antigens Pertussis Toxoid Filamentous Haemagglutinin;poliovirus (inactivated) type 1 (Mahoney) type 2 (MEF-1) type 3 (Saukett);Haemophilus influenzae type b polysaccharide (Polyribosylribitol Phosphate) conjugated to Tetanus protein;tetanus toxoid) — Sanofi Winthrop Industrie
The European Medicines Agency authorised Hexacima, a hexavalent vaccine combining hepatitis B surface antigen, diphtheria toxoid, pertussis …
-
CLINICAL_TRIALS trial_result · 2025-09-22Clinical Trial Update: Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand [Phase 3]
Phase 3 study evaluating the DTwP-HepB-Hib-IPV (SHAN6) vaccine administered with routine vaccines in healthy infants and toddlers in Thailan…
-
CLINICAL_TRIALS trial_result · 2025-09-16Clinical Trial Update: Study to Compare the Anti-tetanus Neutralizing Antibody Titers and Safety of TNM002 Injection With Human Tetanus Immunoglobulin or Placebo in Adult Volunteers [Phase 2]
Phase 2 trial comparing TNM002 anti-tetanus neutralizing antibody with human tetanus immunoglobulin or placebo in adults; the study evaluate…
-
CLINICAL_TRIALS research · 2025-09-15Clinical Trial Update: A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed [Phase 3]
Phase 3 trial update for Beijing Institute of Biological Products' Diphtheria, Tetanus and Acellular Pertussis vaccine adsorbed; the study i…
-
CLINICAL_TRIALS trial_result · 2025-09-12Clinical Trial Update: Study to Evaluate the Immune Response After Booster Vaccination With Tdap-IPV Vaccine (Against Tetanus, Diphtheria, Pertussis and Poliomyelitis) in Children Who Received Different Pertussis Primary Vaccine Regimens in Republic of South Africa [Phase 4]
This Phase 4 clinical trial assesses immune responses after a booster vaccination with Tdap-IPV in children who previously received differen…
-
CLINICAL_TRIALS trial_result · 2025-08-15Clinical Trial Update: Inter-lot Consistency Clinical Trial of Adsorbed Cell-free DTP (Three-component) Combined Vaccine [Phase 3]
Phase 3 inter-lot consistency study update for an adsorbed cell-free diphtheria-tetanus-pertussis vaccine developed by CanSino Biologics.
-
CLINICAL_TRIALS research · 2025-08-08Clinical Trial Update: Adsorption of Cell-free Diphtheria and Tetanus (Three-component) Combined With Vaccine Phase III Clinical Trial [Phase 3]
Phase 3 clinical trial evaluating an adsorbed, three-component cell-free diphtheria-tetanus vaccine for prevention of pertussis, diphtheria,…